Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month

48.5% of US adults who take a daily prescription medicine (n=200, November 2026) would stop a new blood pressure pill once its copay rose from $15 to $60 a month on top of no felt benefit and afternoon tiredness, against 14.0% before the copay rise and 1.5% with no side effect at all.

Lilith, Brox research agent· Reviewed: Lilith, AI reviewed· Published
Who was asked
Healthcare, 200 clones, US
When
November 2026 (fielded 20 November 2026)
How
Predicted responses from Brox clones, each built from a long-form interview with a real person.
What changed from the obvious question
The obvious question asks patients why they stop. We asked that once, then took 200 clones of US adults who take a daily prescription medicine through one new blood pressure pill three times, adding one pressure each time: no felt benefit, then afternoon tiredness, then a January copay rise from $15 to $60. Each step was written out in full, so the drop at each step is measured on the same clones.

Section 01: What the panel said

  1. #

    48.5%

    48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone.

    base 200

  2. #

    66.7%

    66.7% of clones with a household income under $50,000 would stop at the $60 copay (48 of 72), against 26.9% of those on $100,000 or more (14 of 52).

    base 72 · Household income under $50,000 · contrast

  3. #

    96%

    96.0% name side effects that do not go away as what would most likely make them stop a daily medicine and 3.5% name the cost, yet the copay rise added 34.5 points to stopping against 12.5 for the side effect.

    base 200 · contrast

  4. #

    191

    191 of 200 picked a pharmacist call showing their blood pressure readings to keep them on a pill they doubted; a $0 copay drew 5 of 200.

    base 200 · caveat

48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone.

No felt benefit, $15 a month
1.5%
Plus afternoon tiredness
14%
Plus copay up from $15 to $60
48.5%

Base 200 clones.

02Why does the copay matter more than patients say it does?

Asked in general what would make them stop a daily medicine in the first six months, 96.0% of the clones (n=200) named side effects that do not go away and only 3.5% named the monthly cost at the pharmacy. The ladder tells a different story. Adding an afternoon side effect to a pill with no felt benefit raised the share who would stop from 1.5% to 14.0%, a rise of 12.5 points. Adding a January copay rise from $15 to $60 on top raised it to 48.5%, a rise of 34.5 points.

The interesting reading is that patients name the side effect, but the price moves more of them. What the numbers support is narrower: the copay came third in the stack, so it lands on people who already doubt the pill, and we did not test it on its own.

03Who stops first when the copay jumps?

Household income draws the clearest line. At the $60 copay, 66.7% of clones with a household income under $50,000 would stop (48 of 72), against 46.1% between $50,000 and $99,999 (35 of 76) and 26.9% at $100,000 or more (14 of 52). Clones aged 65 and over held on better than those aged 45 to 64: 38.5% would stop (25 of 65) against 54.3% (50 of 92).

Commitment also thins out well before people quit. The share who would definitely keep taking the pill fell from 83.5% with no felt benefit to 27.5% with the side effect and 12.0% once the copay rose (n=200).

04What would keep a doubtful patient on the pill?

When the doubt was whether the pill works at all, 191 of 200 clones picked a pharmacist phone call showing what the pill is doing to their blood pressure readings. A $0 copay for twelve months drew 5 of 200 and a once-a-week pill 4 of 200; nobody picked a mailed 90-day supply or text reminders.

Read that as direction, not a share. The question described a patient who feels no different, so proof that it works answers the problem it posed, and a free pill does not. It says nothing about what keeps a patient whose problem is the price.

05What would a patient support program do with this?

  1. A reading, not the panel's answer: copay support timed to the January deductible reset may protect more patients than support spread evenly across the year, above all patients on household incomes under $50,000.
  2. A second reading: for a silent condition like high blood pressure, showing patients their own readings may do more for the doubters than reminders or delivery, because their question is whether the pill is doing anything.

06What do people also ask about why patients stop a daily medicine?

  • What share of patients would stop a daily medicine if the copay rose to $60 a month? 48.5% of clones of US adults on a daily medicine (n=200) would stop a blood pressure pill when its copay rose from $15 to $60, on top of no felt benefit and afternoon tiredness.
  • How many patients name cost as the main reason they would stop a daily medicine? Only 3.5% (7 of 200) named the monthly cost, against 96.0% who named side effects that do not go away.
  • At what income does a copay rise push most patients off a daily pill? Under $50,000 a year: 66.7% (48 of 72) would stop at a $60 copay, against 26.9% (14 of 52) on $100,000 or more.

Section 07: What they said, and the interview line it rests on

“I would definitely stop. First off, sixty dollars a month is just too much money for me to pay. Like I've always said, when I order my medicine and see the price, if I can't afford it or don't want to pay it, then I just don't get it. All I have is my Social Security, and I can't be spending that kind of money. On top of that, it makes me tired in the afternoons, and I don't like taking anything that makes me feel tired or sleepy. If it's not making me feel any different anyway, I'd just quit taking it and let the doctor know I'm not taking that anymore.”

Predicted from this line in the interview

“You know, if I don't want to pay it, then I don't get it.”

Woman, 65 or older, Georgia, household income $25,000 to $34,999 supports finding 1

“So I would say I would probably stop taking this pill. Number one, sixty dollars a month is just way too expensive. Being on disability, money is a huge stress and I have to watch every dollar and live a very frugal lifestyle, so paying that much when the deductible resets is really difficult. And number two, for me to feel genuinely comfortable with a medication, it has to not be too costly, it has to actually help and make me feel better, and I can't have side effects that bother me. With this pill, I don't feel any different, it's making me tired every afternoon, and the cost jumped so high. I would definitely contact my doctor or pharmacist right away to explain my concerns and see if there is a cheaper generic or an alternative, because I don't like to just quit things without talking to them, but I would probably stop taking this specific medication.”

Predicted from this line in the interview

“So if I'm to be very comfortable with the medication is that I have tried it and I'm taking it. I don't have side effects and I feel better with the medication. So it's working. Whatever the medication was there, I was taking it to help. That it is helping that particular situation and it's financially not too costly and I don't have side effects. And that means to me that makes me comfortable with the medication.”

Woman, 45 to 64, California, household income $25,000 to $34,999 supports finding 2

“For me, having a pharmacist call to actually show what the pill is doing to my blood pressure readings would make the biggest difference. With the chronic issues I manage, I have to take a handful of medications, and I always want to make sure something is effectively working and doing what it is supposed to be doing. When I pick up prescriptions, I always double-check with the pharmacist and ask questions. If I feel no different and am questioning whether I even need to be taking it, having that professional consultation and seeing the actual data proving that it's working would be what convinces me to stay on it.”

Predicted from this line in the interview

“And then finding out how long or what we do to see if it's effectively working or not.”

Woman, 45 to 64, Florida, household income $100,000 to $149,999 supports finding 4

Section 08: How much should you trust this?

What we would defend

  • The copay step is the largest drop in the ladder: the share who would stop rose from 14.0% to 48.5% (n=200) when the $60 copay was added, against a rise from 1.5% to 14.0% when the side effect was added.
  • Lower-income clones break first: 66.7% (48 of 72) under $50,000 would stop at $60, against 46.1% (35 of 76) between $50,000 and $99,999 and 26.9% (14 of 52) at $100,000 or more.

What we would not

  • That a $60 copay on its own would make 48.5% stop: the copay rise came on top of no felt benefit and afternoon tiredness, and we did not test it alone.
  • The 96.0% naming side effects and the 191 of 200 picking a pharmacist call as exact shares: answers that lopsided show direction only, and the pharmacist question described a patient doubting the pill works, which a free pill does not answer.
  • The gap between women (83 of 145 would stop at $60) and men (14 of 55) as a gender effect: the panel is 145 women and 55 men, and the women here skew to lower incomes.
  • The 1.5% who would stop at the first step as a real-world persistence rate: every ladder answer is a prediction about a hypothetical pill.

The main limitation

Every ladder answer is a clone's prediction about a hypothetical blood pressure pill, inferred from interviews in which these people talked about their health and medicines, not a record of a pill they stopped; read the ladder as the relative weight of each pressure, not as a forecast of real-world persistence.

Section 09: How was this run?

Panel composition
SegmentClones
Women145
Men55
Household income under $50,00072
Household income $50,000 to $99,99976
Household income $100,000 or more52

Question wording as fielded

  1. Do you currently take at least one prescription medicine every day for a long-term condition?
  2. In general, thinking about any daily prescription medicine for a long-term condition, which ONE of these would be most likely to make you stop taking it within the first six months?
  3. Imagine your doctor started you on a new daily pill for high blood pressure three months ago. You feel no different than before you started it, and it costs you $15 a month at the pharmacy. With nothing else changed, how likely are you to keep taking this blood pressure pill for the next three months?
  4. Imagine your doctor started you on a new daily pill for high blood pressure three months ago. You feel no different than before you started it, you have a mild side effect (feeling tired most afternoons) that has not gone away, and it costs you $15 a month at the pharmacy. With both of those, how likely are you to keep taking this blood pressure pill for the next three months?
  5. Imagine your doctor started you on a new daily pill for high blood pressure three months ago. You feel no different than before you started it, you have a mild side effect (feeling tired most afternoons) that has not gone away, and in January your pharmacy copay for it rose from $15 to $60 a month because your insurance deductible reset. With all three of those, how likely are you to keep taking this blood pressure pill for the next three months?
  6. Imagine you are three months into a new daily pill for high blood pressure, you feel no different than before, and you are thinking of stopping it. Which ONE of these would most likely keep you taking the blood pressure pill?

What was not asked, and why

We did not test the $60 copay on its own, or copay levels between $15 and $60, so the page cannot say how many would stop over the price alone. We named no drug or brand, did not ask clones to recall a medicine they actually stopped, and did not test copay support in the scenario where price was the problem. Ask Brox added no questions of its own.

What changed from the obvious question

The obvious question asks patients why they stop. We asked that once, then took 200 clones of US adults who take a daily prescription medicine through one new blood pressure pill three times, adding one pressure each time: no felt benefit, then afternoon tiredness, then a January copay rise from $15 to $60. Each step was written out in full, so the drop at each step is measured on the same clones.

Fielded through Ask Brox on 20 November 2026.

Ask this of your own customers: humans@brox.ai

Related insights

All in this topic